Aspen Pharmacare (APNHY) Lowered to “Hold” at Zacks Investment Research

Aspen Pharmacare (OTCMKTS:APNHY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. “

How to Become a New Pot Stock Millionaire

APNHY stock traded up $0.05 during mid-day trading on Tuesday, hitting $21.65. The company had a trading volume of 9,753 shares, compared to its average volume of 37,448. The firm has a market cap of $9,642.54, a price-to-earnings ratio of 196.80, a P/E/G ratio of 1.27 and a beta of 0.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.56 and a current ratio of 0.89. Aspen Pharmacare has a 12 month low of $19.45 and a 12 month high of $24.60.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://sportsperspectives.com/2018/04/17/aspen-pharmacare-apnhy-lowered-to-hold-at-zacks-investment-research.html.

Aspen Pharmacare Company Profile

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies branded, OTC, and generic pharmaceutical products, infant nutritionals, and consumer healthcare products. The company offers various branded products for a range of therapeutic categories, including anaesthetics, analgesics, anti-retrovirals, blood and haemopoetic, cardio vascular system, central nervous system, endocrine system, gastro-intestinal tract, infant milk formulations, musculo-skeletal agents, NSAids, oncology, oral hygiene, respiratory system, and urinary tract system, as well as ear, nose, and throat.

Get a free copy of the Zacks research report on Aspen Pharmacare (APNHY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply